Nelly Mugo

Last updated

Nelly Mugo
Nationality Kenyan
Education University of Nairobi
University of Washington
Scientific career
Fields Medicine, HIV
Institutions Kenya Medical Research Institute
University of Washington

Nelly Mugo is a Kenyan obstetrician, gynaecologist and scientist involved in HIV and cervical cancer prevention research. She is a Research Associate Professor, Global Health in the University of Washington and the Center for Clinical Research, Kenya Medical Research Institute. [1] She is also a member of the African Academy of Sciences. [2] In 2021, Mugo became the inaugural recipient of the Gita Ramjee Prize. [3] [4]

Contents

Early life and education

Mugo was one of eight children. [5] She began her medical training at the University of Nairobi in 1981, [5] where she completed degrees in Bachelor of Medicine, Bachelor of Surgery and Master of Medicine. [1] In 2000, she received a degree in Master of Public Health from the University of Washington. [6]

Career

Mugo was trained as a gynaecologist and epidemiologist. [7] She initially began her career at rural hospitals, and, later, the Pumwani Maternity Hospital. [5] She was a clinician and the head of department for research and programs at the Kenyatta National Hospital, and has also provided training and mentorship for medical students. [2] Mugo was an investigator for the Partners PrEP Study, [1] which aimed to use medication to prevent HIV infection. [8] Mugo has contributed to various World Health Organisation initiatives and fora, [9] and was part of a committee that rewrote PrEP guidelines for Kenya's National AIDS and STI Control Programme. [5]

In addition to her work as a researcher, Mugo is also a reproductive health clinical practitioner. She currently leads a clinical trial site in Thika, Kenya, [9] and is also a member of the International Papillomavirus Society's Education Committee. [7]

In 2021, Mugo became the inaugural recipient of the Gita Ramjee Prize for leading female scientists in the field of HIV prevention. [3]

Research

Mugo is a reproductive health specialist known for her research on STIs, notably in HIV and cervical cancer prevention. She has conducted HPV studies among sex workers, and has been involved in HPV vaccines trials. [1]

Mugo was involved in pre-exposure prophylaxis studies as part of the Partner PrEP study, [9] which aimed to improve HIV prevention among serodiscordant couples. She has subsequently become involved in programs to further implement and assess PrEP implementations, [5] as well clinical trials for HIV self-testing methods. [2] Mugo was also a member of the management committee for the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial, which evaluated the risk of acquiring the HIV virus while using contraceptives. [7]

Related Research Articles

<span class="mw-page-title-main">Safe sex</span> Ways to reduce the risk of acquiring STIs

Safe sex is sexual activity using methods or contraceptive devices to reduce the risk of transmitting or acquiring sexually transmitted infections (STIs), especially HIV. "Safe sex" is also sometimes referred to as safer sex or protected sex to indicate that some safe sex practices do not eliminate STI risks. It is also sometimes used colloquially to describe methods aimed at preventing pregnancy that may or may not also lower STI risks.

<span class="mw-page-title-main">Nonoxynol-9</span> Chemical compound

Nonoxynol-9, sometimes abbreviated as N-9, is an organic compound that is used as a surfactant. It is a member of the nonoxynol family of nonionic surfactants. N-9 and related compounds are ingredients in various cleaning and cosmetic products. It is widely used in contraceptives for its spermicidal properties.

Spermicide is a contraceptive substance that destroys sperm, inserted vaginally prior to intercourse to prevent pregnancy. As a contraceptive, spermicide may be used alone. However, the pregnancy rate experienced by couples using only spermicide is higher than that of couples using other methods. Usually, spermicides are combined with contraceptive barrier methods such as diaphragms, condoms, cervical caps, and sponges. Combined methods are believed to result in lower pregnancy rates than either method alone.

Men who have sex with men (MSM) refers to all men who engage in sexual activity with other men, regardless of sexual identity. The term was created by epidemiologists in the 1990s, to better study and communicate the spread of sexually transmitted infections such as HIV/AIDS between all sexually active males, not strictly those identifying as gay or bisexual, but also for example male prostitutes. The term is often used in medical literature and social research to describe such men as a group. It does not describe any specific kind of sexual activity, and which activities are covered by the term depends on context. An alternative term, males who have sex with males is sometimes considered more accurate in cases where those described may not be legal adults.

<span class="mw-page-title-main">HPV vaccine</span> Class of vaccines against human papillomavirus

Human papillomavirus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus (HPV). Available HPV vaccines protect against either two, four, or nine types of HPV. All HPV vaccines protect against at least HPV types 16 and 18, which cause the greatest risk of cervical cancer. It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% efficacy in preventing HPV-positive oropharyngeal cancers. They additionally prevent some genital warts, with the quadrivalent and nonavalent vaccines that protect against HPV types HPV-6 and HPV-11 providing greater protection.

<span class="mw-page-title-main">Pre-exposure prophylaxis for HIV prevention</span> HIV prevention strategy using preventative medication for HIV-negative individuals

Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is a form of pre-exposure prophylaxis to prevent HIV infection, the cause of HIV/AIDS.

<span class="mw-page-title-main">HIV Prevention Trials Network</span>

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. HPTN studies evaluate new HIV prevention interventions and strategies in populations and geographical regions that bear a disproportionate burden of infection. The HPTN is committed to the highest ethical standards for its clinical trials and recognizes the importance of community engagement in all phases of the research process.

<span class="mw-page-title-main">PATH (global health organization)</span> Global health nonprofit

PATH is an international, nonprofit global health organization. PATH is based in Seattle with 1,600 employees in more than 70 countries around the world. Its president and CEO is Nikolaj Gilbert, who is also the Managing Director and CEO of Foundations for Appropriate Technologies in Health (FATH), PATH's Swiss subsidiary. PATH focuses on six platforms: vaccines, drugs, diagnostics, devices, system, and service innovations.

<span class="mw-page-title-main">Sexually transmitted infection</span> Infection transmitted through human sexual behavior

A sexually transmitted infection (STI), also referred to as a sexually transmitted disease (STD) and the older term venereal disease (VD), is an infection that is spread by sexual activity, especially vaginal intercourse, anal sex, oral sex, or sometimes manual sex. STIs often do not initially cause symptoms, which results in a risk of passing the infection on to others. Symptoms and signs of STIs may include vaginal discharge, penile discharge, ulcers on or around the genitals, and pelvic pain. Some STIs can cause infertility.

CONRAD is a non-profit organization scientific research organization that works to improve the reproductive health of women, especially in developing countries. CONRAD was established in 1986 under a cooperative agreement between Eastern Virginia Medical School (EVMS) and the United States Agency for International Development(USAID). CONRAD’s products are developed primarily for women in low-resource settings, in that they are designed to be safe, affordable and user-friendly. CONRAD is led by Scientific and Executive Director Gustavo Doncel, M.D., Ph.D. Primary funding for CONRAD comes from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID), with additional funding from The Bill & Melinda Gates Foundation and the National Institutes of Health (NIH).

<span class="mw-page-title-main">Elioda Tumwesigye</span> Ugandan politician

Elioda Tumwesigye is a Ugandan politician, physician, and epidemiologist who has served as minister of science, technology and innovation in the cabinet of Uganda since June 2016. From March 2015 until June 2016, he served as the minister of health.

Anna-Lise WilliamsonMASSAf is a Professor of Virology at the University of Cape Town. Williamson obtained her PhD from the University of the Witwatersrand in 1985. Her area of expertise is human papillomavirus, but is also known on an international level for her work in developing vaccines for HIV. These vaccines have been introduce in phase 1 of clinical trial. Williamson has published more than 120 papers.

Dr Eugen Molodysky OAM, MMBS is an academic and medical practitioner in preventive medicine and translational research. His research has been published in peer reviewed journals over the last 30 years. He has a life-long professional focus on prevention, preclinical diagnosis and early intervention.

Multipurpose prevention technologies (MPTs) are a class of products designed to address at least two health issues simultaneously, often focusing on sexual and reproductive health which includes contraception, human immunodeficiency virus (HIV) prevention, other sexually transmitted infection (STI) preventions, such as genital infection by human simplex virus (HSV) infection and human papillomavirus (HPV) infection. For example, MPTs can combine contraception and HIV prevention, contraception and other STI prevention, or the prevention of multiple STIs. Since the simultaneous use of multiple products with a single indication against each specific sexual and reproductive health issue is inconvenient, this method may affect adherence. As a result, the goal of developing a MPT as an all-in-one product is to combat this issue.

Elizabeth Anne Bukusi FAAS is a research professor working within the field of obstetrics and gynaecology, and global health. Bukusi's main areas of research focus around sexually transmitted infections, women's health, reproductive health, and HIV care, prevention and treatment. Bukusi is the Chief Research Officer at the Kenya Medical Research Institute (KEMRI) and led a "landmark" study on the use of PrEP in Kenya.

Gita Ramjee was a Ugandan-South African scientist and researcher in HIV prevention. In 2018, she was awarded the ‘Outstanding Female Scientist’ award from the European and Developing Countries Clinical Trials Partnership. She died in Umhlanga, Durban, South Africa, from COVID-19 related complications.

<span class="mw-page-title-main">Jeanne Marrazzo</span> American microbiologist

Jeanne Marisa Marrazzo is an American physician-scientist and infectious diseases specialist. She was the director of the University of Alabama School of Medicine Division of Infectious Diseases and focused on prevention of HIV infection using biomedical interventions. Marrazzo is a fellow of the American College of Physicians and Infectious Disease Society of America. On August 2, 2023 Lawrence A. Tabak, acting director for the National Institutes of Health (NIH), named Jeanne M. Marrazzo as director of NIH’s National Institute of Allergy and Infectious Diseases.

<span class="mw-page-title-main">Michel Alary</span> Canadian academic, doctor

Michel Alary is a Canadian academic, doctor of preventive medicine and a health researcher. He is a Professor of Social and Preventive Medicine at Université Laval and the director of population health research at the Research Centre of the CHU de Quebec – Université Laval. He also serves as a Medical Consultant at the Institut national de santé publique du Québec. Alary has published over 260 research papers and has produced major reports for the World Bank and UNAIDS about HIV in sub-Saharan Africa. He also evaluated the Bill & Melinda Gates Foundation's India AIDS Initiative for which his project received the Avahan Recognition Award. He has conducted epidemiological and preventive research on blood-borne infections, HIV and other Sexually Transmitted Diseases (STD) among the most vulnerable populations in developed and developing countries.

Pamela Toliman is a medical researcher from Papua New Guinea (PNG) who has researched areas such as sexually transmitted diseases, HIV/AIDS, cervical cancer and COVID-19.

<span class="mw-page-title-main">Julia C. Gage</span> American cancer epidemiologist

Julia C. Gage is an American cancer epidemiologist who researches cervical screening and the human papillomavirus infection. She is a staff scientist in the clinical genetics branch at the National Cancer Institute.

References

  1. 1 2 3 4 "Nelly Mugo Research Associate Professor, Global Health". University of Washington . Retrieved September 19, 2021.
  2. 1 2 3 "Nelly Mugo". African Academy of Sciences. Archived from the original on January 9, 2023. Retrieved September 19, 2021.
  3. 1 2 Nosipho (January 29, 2021). "Dr Nelly Mugo becomes 1st recipient of Gita Ramjee Prize at HIVR4P //Virtual 2021". www.auruminstitute.org. Retrieved June 2, 2022.
  4. ↑ "Nelly Mugo Honored for Research in HIV Prevention". globalhealth.washington.edu. January 28, 2021. Retrieved April 16, 2022.
  5. 1 2 3 4 5 Kirby, Tony (April 29, 2017). "Nelly Mugo—rolling out PrEP in Kenya". The Lancet. 389 (10080): 1689. doi:10.1016/S0140-6736(17)31068-1. PMID   28463131. S2CID   13315559 – via ProQuest.
  6. ↑ "Nelly Mugo". The Conversation. November 21, 2016. Retrieved June 2, 2022.
  7. 1 2 3 "Mugo, Nelly". IPVS. Retrieved June 2, 2022.
  8. ↑ "Partners PrEP Study | International Clinical Research Center". depts.washington.edu. Retrieved June 2, 2022.
  9. 1 2 3 "Nelly Mugo, MbCHB, MMED (Ob,Gyn) MPH | AME". academicmedicaleducation.com. Retrieved April 16, 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.